Circulating Tumor DNA Predicts Progression-Free Survival in Hodgkin Lymphoma

The primary objective in managing Hodgkin lymphoma has shifted from simply achieving a cure to balancing high efficacy with the reduction of long-term treatment-related toxicities [1]. While interim positron emission tomography remains the standard for assessing early treatment response, its sensitivity and specificity for predicting relapse are not absolute, necessitating more precise biomarkers [1, 2]. Minimal residual disease monitoring, a technique that detects trace amounts of cancer-derived genetic material in the blood, has already demonstrated utility in other B-cell malignancies by identifying patients at high risk of early progression [3, 4, 5]. In the context of aggressive lymphomas, the ability to quantify molecular response early in the treatment course could facilitate a more personalized approach to therapy [6]. A recent study evaluates how a validated circulating tumor DNA sequencing assay might enhance these prognostic efforts during frontline treatment, potentially allowing clinicians to adjust therapies based on individual molecular risk.